Apnimed IPO

Develops oral pharmacologic therapies.

NASDAQ: APMD

Buy

Buy Private Stock

Sign up to invest in private companies like Apnimed before their IPO.

Sell

Sell Private Stock

Sign up to sell private companies like Apnimed before their IPO.

Overview

Apnimed completed their IPO on July 31, 2026. Now that Apnimed is a public company, Nasdaq Private Market does not actively track its performance. The data below is for reference before the company’s IPO.

Apnimed is focused on developing oral pharmacologic therapies for obstructive sleep apnea (OSA) and related sleep disorders. Their investigational oral therapy, AD109, aims to simplify treatment and improve oxygenation for individuals with OSA.

Sector

Healthcare & Life Sciences

Founded

2014

Headquarters

Cambridge, MA

Apnimed Funding

Apnimed Funding History Pre-IPO

Gain insights into Apnimed funding history prior to their IPO, including the funding round, time period, and amount raised.

Financing Round Date Amount Price per share Valuation
Round Date Amount PPS Valuation
Series D Mar 11, 2026 25M
XXXXX
XXXXX
Series D Apr 23, 2025 16M
XXXXX
XXXXX
Series C Dec 22, 2022 80M
XXXXX
XXXXX
Series C Nov 01, 2022 25M
XXXXX
XXXXX
Series C Apr 28, 2022 37M
XXXXX
XXXXX
Series B Mar 12, 2021 25M
XXXXX
XXXXX
Series B Mar 31, 2020 15M
XXXXX
XXXXX
Series A Aug 07, 2019 6M
XXXXX
XXXXX
Series A Jan 10, 2019 10M
XXXXX
XXXXX
Series A Aug 09, 2018 5M
XXXXX
XXXXX
Series A Jun 25, 2018 5M
XXXXX
XXXXX

Access the PPS, Valuation details, and a wealth of other data by signing up. Source: Nasdaq Private Market

Buy

Buy Private Stock

Sign up to invest in private companies like Apnimed before their IPO.

Sell

Sell Private Stock

Sign up to sell private companies like Apnimed before their IPO.

Apnimed Management Team

Apnimed people and management – Prior to IPO

  • CEO
    Lawrence G. Miller
  • Chief Business Officer
    Barry Wohl
  • Chief Medical Officer
    Ron Farkas
  • Chief Scientific Officer
    Luigi Taranto Montemurro
  • COO
    Dennis P. Molnar
  • Chief Commercial Officer
    Graham Goodrich
  • Chief Financial Officer
    Ramzi Benamar

Investors

Major Apnimed investors

  • Sectoral Asset Management

  • Alpha Wave Ventures

  • Tao Capital Partners

  • NexPoint Capital

  • Morningside Venture Investments

  • Columbia Seligman Investments

Apnimed Valuations & Financials

Looking for private company valuations and share price data?

Nasdaq Private Market Data & Intelligence is the private company valuation database covering 4,000+ venture-backed companies with daily pricing, financing history, and secondary market activity. View real-time NPM data on pre-IPO companies including valuations, private company comparable transactions, and historical share price information — the private company due diligence data sources institutional investors rely on.

Similar Companies

Explore companies

like Apnimed

  • Cerebral

    Healthcare & Life Sciences

    Telemedicine mental health startup, providing evidence-based therapeutic techniques and medication management.

  • Roman Health Ventures-Logo

    Ro

    Healthcare & Life Sciences

    Healthcare technology for a patient-centric healthcare system.

  • Somatus-Logo

    Somatus

    Healthcare & Life Sciences

    Integrated care for patients with or at risk of developing kidney disease.

  • Cityblock Health-Logo

    Cityblock

    Healthcare & Life Sciences

    Tech-driven care provider for communities with complex needs.

  • Benchling-Logo

    Benchling

    Healthcare & Life Sciences

    Cloud based platform for research and development in biotechnology.

  • Insitro-Logo

    insitro

    Healthcare & Life Sciences

    Drug discovery and development company.

  • Cedar Inc-Logo

    Cedar

    Healthcare & Life Sciences

    The tech platform uses modern intelligence to improve healthcare financial experiences for everyone.

  • Virta Health-Logo

    Virta Health

    Healthcare & Life Sciences

    Online specialty medical clinic focused on reversing type 2 diabetes.

  • Weareresilience-Logo

    Resilience

    Healthcare & Life Sciences

    Operates as technology-focused biomanufacturing company dedicated to broadening access to complex medicines.

FAQ

Questions?

We have answers

Buy Apnimed Stock

Apnimed became publicly traded following its IPO on July 31, 2026, its shares now trade on public stock exchanges under the ticker symbol NASDAQ: APMD. Before the IPO, Apnimed stock was privately held and available only through private market transactions.

If you’re an accredited investor looking to purchase pre-IPO shares in a private company, Nasdaq Private Market can help you get started. Learn more about investing in the private market or sign up for free to explore available opportunities. Learn more about how private company shares trade prior to an IPO on our investors page.

Sell Apnimed Stock

Following its IPO on July 31, 2026, Apnimed shares trade on public stock exchanges, allowing shareholders to sell stock through a traditional brokerage.

If you currently hold shares in a private company, Nasdaq Private Market may be able to help you explore your sell private company stock. Our platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To understand how employees sell shares before a company goes public, visit the Employee Shareholders page.

 

Apnimed Stock Price

Following the IPO, Apnimed stock prices can now be viewed publicly on major exchanges. Investors and interested parties can find the current stock price by searching Apnimed’s ticker symbol on financial platforms such as Nasdaq.com or through their preferred brokerage platform.

Apnimed Stock Ticker Symbol

Following its IPO on July 31, 2026, Apnimed stock now trades on public markets under the ticker symbol NASDAQ: APMD. You can view real-time stock information through widely used financial data platforms.

Criteria to Sell Apnimed Stock

Following the Apnimed IPO, public shares can be sold through any brokerage.

Nasdaq Private Market works with employees, ex-employees, and other private company shareholders of pre-IPO companies to sell their shares. The Nasdaq Private Market platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To learn more about how to sell private company stock, visit the Employee Shareholders page.

Read more about how to sell shares of a private company and eligibility for selling privately held stock:

 

Criteria to Buy or Invest in Apnimed Stock

Following Apnimed’s initial public offering on July 31, 2026, its shares are now listed on a public exchange and available for purchase through a brokerage account. Investors interested in buying Apnimed stock can do so through their preferred broker, just as they would with any other publicly traded security.

Nasdaq Private Market continues to work with investors seeking exposure to private company opportunities prior to IPO. Through structured transactions and curated offerings, investors can participate in private market activity before companies enter the public markets.

Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.

Apnimed Stock Settlement

Since Apnimed is now publicly traded, public-market share transfers and settlement occur automatically through a brokerage or exchange.

Nasdaq Private Market supports transfer and settlement for privately held company equity. In order to buy or sell private company stock, share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patented Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.

To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.

Apnimed IPO

Apnimed completed its IPO on July 31, 2026, and is now publicly available through major financial sources.